Navidea Biopharmaceuticals Inc (NAVB)

[casperboo]

Today's options make me think that a buyout may be coming soon to a theater near us all for around 3.50 per share - and fine by me such would be, as this management team has been paid an undue fortune over the past 3 years to repeatedly drop the ball and declare victory. If Crede hasn't sold yet, they'll make out great at 3.50. If they have sold, it makes me wonder who they know at Navidea to facilitate such a ridiculous deal to the detriment of longs.

FWIW, if sales are below $400,000, I expect a shareholder lawsuit to be filed, as the company was exceptionally optimistic about Q4 sales at the December 5th NYC conference. The nonsense has gone on long enough. Ownership and control of this company needs to be steered by competency, not overpaid incompetency (which has often been deliberate imo).